Saudi Arabia SFDA Registered Devices Teardown & Channel Map
A database teardown of the 163,185 medical devices registered under Saudi Arabia's SFDA, detailing MDMA risk class splits, manufacturer concentration, and AR lock-in risks.
Saudi Arabia SFDA Registered Medical Devices Teardown: 163,185 MDMA Listings, IVD-vs-MD Split, Risk-Class Mix, and Manufacturer Concentration
Saudi Arabia represents the largest and most lucrative medical device market in the Gulf Cooperation Council (GCC) region. Industry estimates typically value the Kingdom's medtech sector in the low single-digit billions of US dollars, expanding at a high-single-digit annual growth rate, fueled by the government's ambitious Vision 2030 program. Vision 2030 aims to privatize healthcare services, expand clinical infrastructure, and localize medical manufacturing. Despite local manufacturing initiatives, the Saudi healthcare system remains highly dependent on international medical technology, with the large majority of devices imported from the United States, Europe, and Asia. (Market-size and import-share figures above are industry estimates, not SFDA data; the registry counts in this teardown are the authoritative figures.)
For regulatory affairs (RA) managers, market-access directors, and international sales executives, securing regulatory clearance in Saudi Arabia is the primary gate to the entire Middle East. The market is overseen by the Saudi Food and Drug Authority (SFDA), which enforces a highly rigorous, centralized registration system. Specifically, the Medical Devices Sector of the SFDA governs the clearance of all medical equipment, in vitro diagnostics (IVDs), and active implantables through the Medical Devices Marketing Authorization (MDMA) process.
To help market entrants size their therapeutic segments, identify potential local partners, and understand competitive concentration, this article provides a detailed data teardown of the official SFDA registered medical device database. Our analysis is based on the SFDA public registry database (June 2026 snapshot), comprising 163,185 unique device listings.
Skip to Your Scenario
To help you quickly navigate this comprehensive guide, select the scenario that best matches your current strategic objective:
- How many medical devices are registered and what is the active vs. suspended split? — Sizing the active market.
- What is the split between medical devices, IVDs, and AIMDs? — Therapeutic segment analysis.
- What is the risk-class distribution & the dual classification reality? — Understanding EU-legacy vs. GHTF A/B/C/D.
- Which manufacturers hold the most SFDA listings? — Identifying the competitive leaders.
- How concentrated are Saudi Authorized Representatives (lock-in risk)? — Navigating channel lock-in.
- How do SFDA MDMA fees and timelines map onto this risk-class mix? — Budgeting and pipeline planning.
- Side-by-Side Regulatory Comparison: Saudi SFDA vs. UAE MoHAP & GCC Countries — Regional reliance maps.
- Post-Market Technovigilance and Safety Reporting Requirements — Vigilance reporting via the GHAD portal.
- Strategic Recommendations for Saudi Market Entry — Optimizing MDMA groups and AR contracts.
How many medical devices are registered and what is the active vs. suspended split?
The SFDA database snapshot contains 163,185 registered device listings. This represents the largest single medical technology register in the Middle East, reflecting Saudi Arabia's dominant buying power and clinical volume.
Our analysis of the status of these listings reveals a highly active registry:
- Active Listings: 162,781 records (99.75%)
- Suspended Listings: 404 records (0.25%)
This extremely low suspension rate indicates that manufacturers and their local representatives actively maintain their registrations. In Saudi Arabia, letting a registration lapse or suspend can lead to severe commercial disruption, as Saudi Customs enforces strict import clearance checks against the SFDA database. When a registration is suspended, it is typically due to a safety alert (such as an active recall), a failure to renew the local Authorized Representative license, or a major compliance failure identified during post-market surveillance.
What is the split between medical devices, IVDs, and AIMDs?
The SFDA categorizes its registry into three distinct device domains based on their technological nature and clinical application. Sizing these domains helps market analysts understand the product mix in the Kingdom:
| Device Domain | Number of Listings | Percentage of Register | Key Examples in Registry |
|---|---|---|---|
| Medical Devices (General) | 112,489 | 68.93% | Syringes, surgical instruments, MRI systems, orthopedic implants |
| In Vitro Diagnostics (IVDs) | 49,599 | 30.40% | PCR test kits, clinical chemistry reagents, blood glucose monitors |
| Active Implantable Medical Devices (AIMDs) | 1,094 | 0.67% | Pacemakers, implantable cardioverter-defibrillators, cochlear implants |
The data highlights that in vitro diagnostics (IVDs) represent nearly one-third (30.40%) of the entire registry. This is an exceptionally high ratio compared to other developing markets, reflecting the Saudi healthcare system's heavy investment in clinical laboratory networks, automated testing systems, and national diagnostic screening programs.
What is the risk-class distribution & the dual classification reality?
Saudi Arabia is in the process of harmonizing its classification system. Historically, the SFDA operated under a GHTF-reliance model where devices were registered based on their home-market clearance (e.g., US FDA Class II, EU CE Mark Class IIa, etc.). Consequently, the registry contains a mix of EU-style and US-style classifications alongside the SFDA’s native risk-based categories.
Our aggregation of the registry classification field reveals the following distribution:
| Classification Category | Number of Listings | Percentage of Register | Regulatory Pathway Context |
|---|---|---|---|
| General IVD (Others) | 43,270 | 26.52% | Low-to-moderate risk IVD reagents and analyzers |
| Class IIa | 35,398 | 21.69% | Low-to-moderate risk invasive/active devices (EU-reliance) |
| Class I | 33,132 | 20.30% | Low-risk consumables and non-invasive equipment |
| Class IIb | 26,351 | 16.15% | Moderate-to-high risk active/implantable devices (EU-reliance) |
| Class III | 10,439 | 6.40% | High-risk implantable devices (cardiac, orthopedic) |
| Legacy Class II | 9,525 | 5.84% | Legacy registrations transitioned from older GHTF tracks |
| Annex II List B | 1,966 | 1.20% | Moderate-to-high risk diagnostics (legacy EU-reliance) |
| Annex II List A | 1,490 | 0.91% | High-risk clinical blood-screening diagnostics (legacy EU-reliance) |
| Other / Unclassified¹ | 1,614 | 0.99% | Residual: null classification, unclassified devices, self-test IVDs, and a small Class IV tier |
This distribution highlights the "dual classification reality" in Saudi Arabia:
- EU MDR/IVDR Transition: The coexistence of Class IIa/IIb/III alongside legacy Annex II List A/List B and General IVD terms reflects the SFDA’s historical dependence on European CE marking documents.
- The A/B/C/D Native Transition: While the SFDA is transitioning toward a native Class A, B, C, and D risk-based model (aligned with IMDRF standards), the registry database continues to reflect the legacy GHTF classification under which the devices were originally approved. For regulatory affairs teams, this means that while new submissions must map to the native SFDA A/B/C/D fee groups, competitor searches must account for the older EU-legacy terms under which competitor products remain listed.
¹ The "Other / Unclassified" row (1,614 listings, 0.99%) is the residual after the eight named classes. It is composed of records with a null/empty classification (1,235), explicitly "Unclassified Devices" (182), "Self Test" IVDs (160), and a small native "Class IV" tier (37). We deliberately separate this residual rather than fold it into a named risk class, because it is heterogeneous and not comparable to the EU-legacy and IMDRF tiers above.
Which manufacturers hold the most SFDA listings?
Analyzing manufacturer concentration in the SFDA database reveals the dominant players in the Saudi medtech market. The table below lists the top manufacturers by the number of active device listings in the registry:
| Manufacturer Name | Registry Count | Primary Product Niche | Headquarters Country |
|---|---|---|---|
| Roche Diagnostics GmbH | 3,438 | In Vitro Diagnostics (IVD) | Germany |
| Aesculap AG | 2,627 | Surgical Instruments & Orthopedics | Germany |
| Cook Inc. | 1,701 | Interventional Devices & Catheters | United States |
| Siemens Healthcare Diagnostics | 1,652 | Clinical Laboratory Diagnostics | Germany |
| Gimmi GmbH | 1,622 | Endoscopy & Surgical Instruments | Germany |
| KLS Martin | 1,530 | Surgical Instruments & Maxillofacial Implants | Germany |
| Leica Biosystems | 1,452 | Pathology & Histology Systems | United Kingdom |
| ASANUS Medizintechnik | 1,448 | Surgical Instruments & Patient Positioning | Germany |
| Smith & Nephew | 1,408 | Wound Care & Orthopedics | United Kingdom |
| Maquet Cardiopulmonary | 1,388 | Cardiovascular & Heart-Lung Systems | Germany |
Key Takeaways from Manufacturer Concentration:
- IVD Dominance: Roche Diagnostics (3,438 listings) and Siemens Healthcare Diagnostics (1,652 listings) represent massive shares of the registry. This correlates with the large volume of clinical reagent listings required to support automated laboratory instruments.
- German Manufacturing Dominance: Out of the top ten manufacturers, seven register through German entities (Roche Diagnostics GmbH, Aesculap, Siemens, Gimmi, KLS Martin, ASANUS, and Maquet), with the United Kingdom (Leica Biosystems, Smith & Nephew) and the United States (Cook) rounding out the top ten. This reflects the strength of German surgical-instrument and diagnostics manufacturers in establishing deep local distribution channels into Saudi clinical procurement.
- Consumables vs. Active Devices: Surgical instrument manufacturers like Aesculap, Gimmi, and ASANUS maintain large numbers of listings because their portfolios consist of thousands of individual surgical tools, each requiring its own listing. Note that Medtronic (1,338 listings) and CareFusion (1,173 listings) sit just outside the top ten, at positions 11 and 12.
How concentrated are Saudi Authorized Representatives (lock-in risk)?
For foreign medical device manufacturers, the selection of a local partner is the single most critical commercial and regulatory decision. Under Saudi law, a foreign manufacturer cannot apply for an MDMA directly. You must appoint a licensed local Authorized Representative (AR).
The local AR serves as the legal liaison between the manufacturer and the SFDA, holding the MDMA certificate in their name. Our analysis of the registry shows that the AR landscape is highly concentrated:
- The Largest AR (ARL-2019-MD-2982): Holds 3,243 active device listings — roughly 2% of the entire national register concentrated under a single license.
- Top 10 ARs: Collectively hold about 12% of all registered devices in the Kingdom. The largest AR codes each hold 1,600–3,200 listings (for example ARL-2019-MD-3382 with 2,218 and ARL-2019-MD-2819 with 1,995).
- Who Holds These Codes: The public registry snapshot identifies authorized representatives by their SFDA license code (ARL-...) rather than by trading name, so a single code can sit behind a major Saudi distributor or an independent regulatory firm. Well-known Saudi healthcare distributors that commonly act as (or sit behind) authorized representatives include large groups active in medtech distribution and government procurement.
The Channel Lock-in Risk:
For a new entrant, partnering with a distributor who also acts as your regulatory AR introduces significant commercial lock-in risk:
- Regulatory Control: The MDMA certificate is legally owned by the AR. If the manufacturer decides to switch commercial distributors due to poor sales performance, the AR must formally agree to transfer the MDMA to the new representative.
- Transfer Hurdles: If the relationship sours, the incumbent distributor can refuse to sign the transfer letter or demand a financial settlement. Without their signature, the manufacturer cannot import products. The alternative is to cancel the existing MDMA and submit a completely new application under a new AR, which costs tens of thousands of Riyals in fees and takes months to approve, resulting in a total blackout of product supply.
- Strategic Warning: To mitigate this risk, many mid-sized manufacturers choose to partner with independent, third-party regulatory consulting firms that act as a "neutral AR" of record. The neutral AR holds the MDMA and licenses, allowing the manufacturer to sign multiple commercial contracts with different local sales distributors without regulatory lock-in. For more detailed analysis on managing these distributor channel risks, read our guide on SFDA authorized representative concentration and expiry risk.
How do SFDA MDMA fees and timelines map onto this risk-class mix?
Navigating the SFDA requires a clear understanding of the financial and administrative requirements. The MDMA fee schedule is risk-based, divided into four Fee Groups (FG1 through FG4), plus additional taxes and renewal costs.
SFDA MDMA Fee Schedule (2026):
[!NOTE] The fee figures below are compiled from consultant/secondary fee schedules (e.g., Motaded) and our Saudi SFDA and UAE registration guide; always confirm the current figure on the SFDA/GHAD portal before budgeting, as the authority periodically updates its fee groups.
| Fee Group | Native SFDA Risk Class | New Application Fee (SAR) | Renewal Fee (SAR) | Regulatory Timeline (Target) |
|---|---|---|---|---|
| FG1 | Class A (Low Risk) | SAR 15,000 | SAR 5,000 | 35 Working Days |
| FG2 | Class B (Low-to-Mod Risk) | SAR 19,000 | SAR 5,000 | 35 Working Days |
| FG3 | Class C (Mod-to-High Risk) | SAR 21,000 | SAR 5,000 | 35 Working Days |
| FG4 | Class D (High Risk) | SAR 23,000 | SAR 5,000 | 35 Working Days |
[!IMPORTANT] All official SFDA fees are subject to an additional 15% Value Added Tax (VAT). Minor modifications to an existing MDMA cost SAR 1,100 per application.
Key Application Rules:
- Product Grouping Limits: Under SFDA grouping guidelines, a single MDMA application can group up to 50 individual product listings (SKUs) associated with up to 5 distinct technical files, provided they share the same manufacturer, intended purpose, and risk classification. If a product line spans different risk classes, it must be split into separate MDMA applications.
- Review Timelines: The SFDA's official review timeline is 35 working days (approx. 50 calendar days). However, if the SFDA issues an Additional Information (AI) request, the clock stops. In practice, administrative delays and document audits can extend the actual time to approval to 4 to 6 months for complex Class C and D devices.
The Transition from GHTF Reliance to Native MDR/IVDR Rules
The co-existence of GHTF classifications and native risk classes in the SFDA database highlights the ongoing modernization of the Saudi medical device regulatory regime. In 2021, the SFDA issued the updated Medical Devices and Supplies Regulation, which formally began the transition away from a pure reliance model.
- Prior System: Previously, manufacturers could submit a simplified application by showing a certificate of clearance from one of the founding GHTF jurisdictions (US, EU, Canada, Japan, Australia). The SFDA would perform a secondary administrative review rather than an independent technical evaluation.
- Current System: Under the native rules, the SFDA conducts its own technical file reviews, particularly for high-risk (Class C and D) devices and IVDs. The submission requires a complete Technical File (similar to an EU MDR Technical Documentation or a US 510(k) summary), local testing reports when relevant, and detailed clinical evaluation reports.
- MDMA Renewal Audits: When legacy MDMAs come up for their 5-year renewal, manufacturers must update their dossiers to comply with these native technical standards. This transition is leading to a gradual consolidation of listings in the database as companies choose to retire older, low-volume product codes rather than investing in full native technical updates.
Side-by-Side Regulatory Comparison: Saudi SFDA vs. UAE MoHAP & GCC Countries
When planning Middle East commercialization, manufacturers must compare the regulatory requirements of different jurisdictions. Saudi Arabia (SFDA) and the United Arab Emirates (MoHAP) represent the two primary regulatory gateways in the region.
| Regulatory Element | Saudi Arabia (SFDA) | United Arab Emirates (MoHAP) | Rest of GCC (Oman, Qatar, Bahrain, Kuwait) |
|---|---|---|---|
| Regulatory Authority | Saudi Food & Drug Authority | Ministry of Health & Prevention | Individual Ministries of Health |
| Local Representative Required? | Yes (Authorized Representative) | Yes (Local Sponsor/Distributor) | Yes (Local Licensed Importer) |
| Base Application Fee (Class B/C) | SAR 19,000 – 21,000 (+15% VAT) | AED 5,000 – 8,000 | Varied (typically lower, approx. $500–$1,500) |
| Submission Portal | GHAD system | e-Services Portal | Individual national portals / GCC Centralized |
| Review Timeline (Actual) | 4 to 6 Months | 3 to 5 Months | 2 to 4 Months |
| Home Market Approval Reliance | Strict (FDA, CE, Health Canada, TGA) | High reliance (FDA/CE preferred) | Very high (typically requires prior SFDA or UAE clearance) |
| Post-Market Vigilance Portal | GHAD system (strict reporting) | MoHAP Vigilance Portal | National report submissions |
The comparison highlights that Saudi Arabia's SFDA is the most expensive and administratively demanding regulator in the GCC. However, because of the SFDA’s high standards, securing an MDMA certificate serves as a major benchmark. Other GCC countries (such as Oman or Bahrain) frequently offer accelerated review pathways or simplified reliance pathways for products that have already secured active SFDA clearance. For a broader overview of Middle East entry strategies, consult the Saudi SFDA and UAE registration guide.
Post-Market Technovigilance and Safety Reporting Requirements
Once a device is successfully listed, compliance duties shift to post-market surveillance. The SFDA operates one of the most vigilant safety tracking systems in the world, managed through the Saudi Vigilance System (GHAD):
- Adverse Event Reporting Timelines:
- Death or Serious Injury: If a device is suspected of causing death or a serious deterioration in health, the local AR must report the event to the SFDA within 10 calendar days of becoming aware.
- Public Health Threat: Events representing an immediate public health threat must be reported within 2 calendar days.
- Minor Malfunctions: Minor malfunctions or labeling errors must be reported within 30 calendar days.
- Field Safety Corrective Actions (FSCAs): When a manufacturer initiates a global recall or field safety notice (FSN), the local AR must submit the corrective action plan to the SFDA within 10 working days. All local stock must be quarantined, and affected clinics must be notified in writing.
- Periodic Safety Update Reports (PSURs): For high-risk Class C and D implantable devices, the SFDA reserves the right to request annual PSUR summaries detailing global sales volume, local implant counts, and adverse event rates.
Strategic Recommendations for Saudi Market Entry
To navigate this highly competitive, highly regulated market, new entrants should implement the following regulatory and commercial strategies:
- Optimize MDMA Grouping: Do not submit applications product-by-product. Work with your RA team to maximize the grouping rules (up to 50 products/5 technical files per MDMA). Grouping accessories and main units under a single application can save hundreds of thousands of Riyals in application fees.
- AR Contract Safeguards: If you choose to appoint a commercial distributor as your regulatory AR, include a mandatory "AR Transfer Clause" in your commercial agreement. This clause should legally obligate the distributor to transfer the MDMA certificates to a new representative within 30 days of contract termination, with pre-defined financial terms or zero penalties.
- Consider a Neutral AR: For long-term flexibility, evaluate using an independent third-party Authorized Representative. This allows you to split the market geographically (e.g., Eastern, Western, and Central regions) and appoint different local sales distributors for public tenders (such as NUPCO procurement) and private hospital chains. For details on how government procurement operates downstream of registration, see our guide on Saudi NUPCO medical device procurement.
- Prepare for Arabic Labeling: The SFDA enforces strict labeling guidelines. While professional-use devices can be labeled in English, any home-use device (such as blood glucose monitors or nebulizers) must feature bilingual English/Arabic labeling and packaging.
FAQs
What does MDMA mean and how is it different from an SFDA product listing?
A Medical Devices Marketing Authorization (MDMA) is the formal regulatory clearance certificate issued by the SFDA that allows a specific medical device system to be imported and sold in Saudi Arabia. An SFDA product listing refers to the individual device SKU or model entry recorded in the registry under that MDMA license. A single MDMA can contain dozens of product listings.
Why does the SFDA database still show EU-style classes alongside A/B/C/D?
The SFDA originally operated a GHTF-reliance model where registrations were based on home-market approvals (such as CE marking). Consequently, older active registrations are still categorized under EU classes (I, IIa, IIb, III) or legacy GHTF groups. While the SFDA is transitioning to a native Class A/B/C/D model, these legacy classification terms remain in the registry database until the respective MDMAs are renewed and transitioned.
How many IVDs vs. medical devices are registered in Saudi Arabia?
Our teardown of the registry reveals that the database contains 112,489 medical devices (68.9%), 49,599 in vitro diagnostics (IVDs) (30.4%), and 1,094 active implantable medical devices (AIMDs) (0.7%).
Which single authorized representative holds the most SFDA device listings?
The single largest local Authorized Representative (ARL-2019-MD-2982) holds 3,243 active device listings in the registry, representing a high concentration of market access under a single local entity.
Can a foreign manufacturer register a medical device in Saudi Arabia without a local office?
No. Foreign manufacturers cannot directly apply to the SFDA for an MDMA or hold establishment licenses. You must legally appoint a local Authorized Representative (AR) who holds a valid SFDA establishment license (MDEL). The AR acts as the legal holder of the MDMA certificates.
How does the SFDA handle combination products (drug-device and device-drug combinations)?
Combination products are evaluated jointly by the Medical Devices Sector and the Drug Sector of the SFDA. The primary mode of action (PMOA) determines which sector leads the review:
- If the PMOA is therapeutic/pharmacological, it is registered as a drug with a secondary device review.
- If the PMOA is physical/mechanical (e.g., prefilled syringes), it is registered as a device with a secondary drug review. The application must be submitted via the Unified GHAD Portal, and fees are determined based on the primary classification pathway.
Internal Links and Context
- For an overview of how Saudi Arabia's regulatory framework compares to neighboring markets, read the Saudi SFDA and UAE registration guide.
- To understand the commercial channel concentration and risks of local representatives in the Kingdom, see our analysis of SFDA authorized representative concentration and expiry risk.
- To see how registrations translate into government sales, consult the Saudi NUPCO medical device procurement playbook.
- To compare the SFDA teardown with other country registries, read the Chile ISP registered medical devices teardown and the Pakistan DRAP registered medical devices teardown.